DAFTAR PUSTAKA

1. Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. *Histopathology.* 2020;76(2):151–156.
2. Da Silva APF, Mello LDA, Dos Santos ERR, Paz ST, Cavalcanti CLB, Melo-Junior MR De. Histopathological and digital morphometrical evaluation of uterine leiomyoma in Brazilian women. *Obstet Gynecol Int.* 2016;2016:1–7.
3. Han X, Kang J, Zhang J, Xiu J, Huang Z, Yang C, et al. Can the signal-to-noise ratio of choline in magnetic resonance spectroscopy reflect the aggressiveness of endometrial cancer? *Acad Radiol.* 2015;22(4):453–459.
4. Camponovo C, Neumann S, Zosso L, Mueller MD, Raio L. Sonographic and magnetic resonance characteristics of gynecological sarcoma. *Diagnostics.* 2023;13(7):1223.
5. Rahimifar P, Hashemi H, Malek M, Ebrahimi S, Tabibian E, Alidoosti A, et al. Diagnostic value of 3 T MR spectroscopy, diffusion-weighted MRI, and apparent diffusion coefficient value for distinguishing benign from malignant myometrial tumours. *Clin Radiol.* 2019;74(8):571.e9–571.e18.
6. Takeuchi M, Matsuzaki K, Nishitani H. Uterine leiomyoma and sarcoma: differentiation with in vivo proton MR spectroscopy. *Magn Reson Med Sci.* 2013;12(3):193–199.
7. Yao N, Li W, Xu G, Duan N, Yu G, Qu J. Choline metabolism and its implications in cancer. *Front Oncol.*2023;13:1234887.
8. Satta S, Dolciami M, Celli V, Di Stadio F, Perniola G, Palaia I, et al. Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters. *Br J Radiol.* 2021;94(1125):20210054. doi:10.1259/bjr.20210054.
9. Ytre-Hauge S, Esmaeili M, Sjøbakk TE, Grüner R, Woie K, Werner HM, et al. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. *Acta Radiol*. 2017;0(0):1–9. doi:10.1177/0284185117733297.
10. Zhang J, Liu Q, Li J, Liu Z, Wang X, Li N, et al. Magnetic resonance spectroscopy associations with clinicopathologic features of estrogen-

dependent endometrial cancer. *BMC Med Imaging.* 2022;22(1):127. doi:10.1186/s12880-022-00856-9.

11. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri: patients treated in 1996–98. *Int J Gynaecol Obstet.* 2006;95 Suppl 1:S105–43.
12. **Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al.** Revised FIGO staging for carcinoma of the cervix uteri. *Int J Gynecol Obstet.* 2019;145(1):129–135. doi:10.1002/ijgo.12749
13. **Standring S, editor.** *Gray's Anatomy: The Anatomical Basis of Clinical Practice.* 39th ed. London: Elsevier Churchill Livingstone; 2005.
14. **Di Fiore MSH.** *Atlas of Human Histology: With Functional Correlations.* 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
15. **Zhong S, Zhang SY, Xing HJ, Zhang XT, Wang G, Bao YP, Fu JN, Yang X.** Revealing histological and morphological features of female reproductive system in tree shrew (*Tupaia belangeri*). *Zoomorphology*. 2018;137(2):191–199. doi:10.1007/s00435-017-0374-7
16. Kinkel K, Kaji Y, Yu KK, Peterson CM, Ernst RD. Radiologic staging in patients with endometrial cancer: a meta-analysis. *Radiology*. 2009;212(3):711-8.
17. Rauch GM, Kaur H, Choi H, Iyer RB. MR imaging of endometrial carcinoma: practical staging approach. *Radiographics*. 2014;34(4):1082-95.
18. Jing X, Wong RW, Rabban JT. Uterine leiomyomas: histopathological evaluation, molecular basis, and clinical significance. *Hum Pathol*. 2013;44(3):293-9.
19. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. *Nat Rev Endocrinol*. 2019;15(12):703-15.
20. Munro MG. Adenomyosis: a systemic disorder? *Am J Obstet Gynecol*. 2019;221(6):591-9.
21. Alfarizan R, Marindawati W. Epidemiological trends and clinical outcomes of adenomyosis in Indonesia: a retrospective study. *J Obstet Gynaecol Res*. 2020;46(4):345-50.
22. Fitrina A, Syukriani Y, Kamal A. Prevalence of adenomyosis in Indonesian population: a histopathological study. *Acta Med Indones*. 2018;50(1):32-7.

23. World Health Organization (WHO). *World Cancer Report 2006*. Lyon: International Agency for Research on Cancer; 2006.
24. Felix AS, Brinton LA. Endometrial cancer incidence and mortality trends by race/ethnicity. *Cancer Epidemiol Biomarkers Prev*. 2018;27(1):1-6.
25. Barjon K, Lyree J. Uterine Leiomyomata. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546680/
26. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4).
27. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: A review. Vol. 111, Environmental Health Perspectives. 2003.
28. Putra AI, Anggraini D. Adenomyosis: pathogenesis and clinical implications. *Obstet Gynecol Sci*. 2022;65(1):1-10.
29. Ciavattini A, Di Giuseppe J, Stortoni P, Montik N, Giannubilo SR, Litta P, et al. Uterine Fibroids: Pathogenesis and Interactions with Endometrium and Endomyometrial Junction. Obstet Gynecol Int. 2013;2013.
30. Yang Q, Madueke-Laveaux OS, Cun H, Wlodarczyk M, Garcia N, Carvalho KC, et al. Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Vol. 13, Cells. Multidisciplinary Digital Publishing Institute (MDPI); 2024.
31. Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. Uterine leiomyomas: Histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics. 1999;19(5).
32. Gadia P, Sankar LN, Jain S, Ukani BV. Role of imaging in female infertility. *Int J Sci Res.* 2017;6(12):332-335.
33. **Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al.** Diagnosing adenomyosis: an integrated clinical and imaging approach. *Hum Reprod Update.* 2020;26(3):392–411. doi:10.1093/humupd/dmz049.
34. Ely, L. K. & Truong, M. (2018) ‘Adenomyosis’, Medscape Drug Reference, pp. 1–16. Available at: https://emedicine.medscape.com/article/2 500101-print.

35. Grasel, Ralf P. et all. Endometrial polyps: MR imaging features and distinction from endometrial carcinoma.2000.*Radiological Society of North America*:47-52.
36. Eveline, dokter et al. Radiology–pathology correlation of endometrial carcinoma assessment on magnetic resonance imaging.2022
37. Bura V, Pintican RM, David RE, Addley HC, Smith J, Jimenez-Linan M, et al. MRI findings in-between leiomyoma and leiomyosarcoma: A Rad-Path correlation of degenerated leiomyomas and variants. Vol. 94, British Journal of Radiology. 2021.
38. Momeni-Boroujeni A, Yousefi E, Balakrishnan R, Riviere S, Kertowidjojo E, Hensley ML, et al. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis. Modern Pathology. 2023;36(4).
39. Ip PPC, Cheung ANY. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Vol. 25, Best Practice and Research: Clinical Obstetrics and Gynaecology. 2011.
40. Blythe JG, Bari WA. Uterine Sarcoma: Histology, Classification, and Prognosis. The Global Library of Women's Medicine. 2009
41. Hensley ML. Uterine Sarcomas: Histology and Its Implications on Therapy. American Society of Clinical Oncology Educational Book. 2012;(32).
42. Menon G, Mangla A, Yadav U. Leiomyosarcoma. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551667/
43. Umamaheswara Reddy V, Agrawal A, Murali Mohan K V., Hegde K V. The puzzle of choline and lipid peak on spectroscopy. Egyptian Journal of Radiology and Nuclear Medicine. 2014;45(3).
44. Lin Y, Hsieh CY, Huang YL, Chen K, Huang YT, Wu RC, et al. Magnetic resonance spectroscopy for risk stratification of sonographically indeterminate ovarian neoplasms: Preliminary study. Diagnostics. 2021;11(10).
45. Venkatesh SK, Gupta RK, Pal L, Husain N, Husain M. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. Journal of Magnetic Resonance Imaging. 2001;14(1).
46. Kim H, Rha SE, Shin YR, Kim EH, Park SY, Lee SL, et al. Differentiating Uterine Sarcoma From Atypical Leiomyoma on Preoperative Magnetic

Resonance Imaging Using Logistic Regression Classifier: Added Value of Diffusion-Weighted Imaging-Based Quantitative Parameters. Korean J Radiol. 2024;25(1).

47. Zhao, J. *et al.* (2021) 'Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments', *BMC Women's Health*, 21(1), p. 312. Available at: https://doi.org/10.1186/s12905-021-01452-9.
48. **Putri BKA.** Resiko terjadinya mioma uteri antara usia menikah dan paritas. *Jurnal Bidan Pintar.* 2020;1(1):41-49. doi:10.30737/jubitar.v1i1.715.
49. Dong, J., Dai, Q. and Zhang, F. (2019) 'The effect of marital status on endometrial cancer-related diagnosis and prognosis: A Surveillance Epidemiology and End Results database analysis', *Future Oncology*, 15(34), pp. 3963–3976. Available at: https://doi.org/10.2217/fon-2019-0241.
50. Chen, N. *et al.* (2025) 'Age at menarche is inversely related to the prevalence of uterine cancer', *European Journal of Medical Research*, 30(1), p. 209. Available at: https://doi.org/10.1186/s40001-025-02472-z.
51. Yang, H.P. *et al.* (2013) 'Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes', *American Journal of Epidemiology*, 177(2), pp. 142–151. Available at: https://doi.org/10.1093/aje/kws200.
52. Karageorgi, S. *et al.* (2010) 'Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004', *International Journal of Cancer*, 126(1), pp. 208–216. Available at: https://doi.org/10.1002/ijc.24672.
53. **Song S, Park B, Park E, Jang H, Lee W, Kim M, et al.** Risk of uterine leiomyomata with menstrual and reproductive factors in premenopausal women: Korea Nurses' Health Study. *BMC Womens Health.* 2023;23(305):1–10. doi:10.1186/s12905-023-02447-4.
54. Gong, T.-T., Wang, Y.-L. and Ma, X.-X. (2015) 'Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies', *Scientific Reports*, 5(1), p. 14051. Available at: https://doi.org/10.1038/srep14051.
55. Harajka, A. *et al.* (2025) 'Association of oral contraceptives and risk of endometrial cancer: A systematic review and meta-analysis', *Acta Obstetricia*

et Gynecologica Scandinavica, 104(4), pp. 591–603. Available at: https://doi.org/10.1111/aogs.15043.

56. Andarieh, M.G. *et al.* (2016) 'Risk Factors for Endometrial Cancer: Results from a Hospital-Based Case-Control Study', *Asian Pacific Journal of Cancer Prevention*, 17(10), pp. 4791–4796. Available at: https://doi.org/10.22034/APJCP.2016.17.10.4791.
57. Sparic R, Mirkovic L, Malvasi A, Tinelli A**.** Epidemiology of uterine myomas: a review. *Int J Fertil Steril.*2016;9(4):424–35. doi:10.22074/ijfs.2015.4599.
58. Bassette, E. and Ducie, J.A. (2024) 'Endometrial Cancer in Reproductive-Aged Females: Etiology and Pathogenesis', *Biomedicines*, 12(4), p. 886. Available at: https://doi.org/10.3390/biomedicines12040886.
59. Zhang, J. *et al.* (2022) 'Whole-lesion apparent diffusion coefficient (ADC) histogram as a quantitative biomarker to preoperatively differentiate stage IA endometrial carcinoma from benign endometrial lesions', *BMC Medical Imaging*, 22(1), p. 139. Available at: https://doi.org/10.1186/s12880-022-00864-9.
60. Woo, S. *et al.* (2024) 'Utility of ADC Values for Differentiating Uterine Sarcomas From Leiomyomas: Systematic Review and Meta-Analysis', *American Journal of Roentgenology*, 223(3). Available at: https://doi.org/10.2214/AJR.24.31280.
61. Gharibvand, M. *et al.* (2019) 'The diagnostic precision of apparent diffusion coefficient (ADC) in grading of malignant endometrial lesions compared with histopathological findings', *Journal of Family Medicine and Primary Care*, 8(10), p. 3372. Available at: https://doi.org/10.4103/jfmpc.jfmpc_142_19.
62. Petrila, O. *et al.* (2024) 'Can the ADC Value Be Used as an Imaging "Biopsy" in Endometrial Cancer?', *Diagnostics*, 14(3), p. 325. Available at: https://doi.org/10.3390/diagnostics14030325.
63. Lura, N. *et al.* (2025) 'Tumor ADC value predicts outcome and yields refined prognostication in uterine cervical cancer', *Cancer Imaging*, 25(1), p. 23. Available at: https://doi.org/10.1186/s40644-025-00828-6.
64. Takeuchi, M., Matsuzaki, K. and Harada, M. (2011) 'Differentiation of benign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T:

preliminary study', *European Radiology*, 21(4), pp. 850–856. Available at: https://doi.org/10.1007/s00330-010-1974-5.

65. Gennarini, M. *et al.* (2025) 'Multi-model quantitative MRI of uterine cancers in precision medicine's era—a narrative review', *Insights into Imaging*, 16(1), p. 113. Available at: https://doi.org/10.1186/s13244-025-01965-z.
66. Malek, M. *et al.* (2020) 'A Diagnostic Algorithm using Multi-parametric MRI to Differentiate Benign from Malignant Myometrial Tumors: Machine-Learning Method', *Scientific Reports*, 10(1), p. 7404. Available at: https://doi.org/10.1038/s41598-020-64285-w.
67. Liu, J. and Wang, Z. (2022) 'Advances in the Preoperative Identification of Uterine Sarcoma', *Cancers*, 14(14), p. 3517. Available at: https://doi.org/10.3390/cancers14143517.
68. Lin, Y. *et al.* (2024) 'Endometrial cancer risk stratification using MRI radiomics: corroborating with choline metabolism', *Cancer Imaging*, 24(1), p. 112. Available at: https://doi.org/10.1186/s40644-024-00756-x.